Clinical pharmacist interventions in managing Key Monitoring Drugs in China [post]

Jing Yang, Lei Zheng, Yuyao Guan, Xiaoli Zhang, Chao Song, Yuchao Gu
2020 unpublished
Background Drug-related problems (DRPs) are common in hospitalized patients using Key Monitoring Drugs. Clinical pharmacy services could minimize drug-related harm and improve patient care.Objective The aim of this study was to standardize the clinical application of Key Monitoring Drugs, reduce the Drug-related problems (DRPs) and drug costs by clinical pharmacist interventions.Methods Clinical pharmacist formulate management measures for Key Monitoring Drugs using evidence-based medicine and
more » ... based medicine and analyze the DRPs of Key Monitoring Drugs over a period of 5 years from 2015 to 2019. The drug cost and DRPs of Key Monitoring Drugs within five years after interventions by clinical pharmacist.Results In 2019, the total cost of the use of Key Monitoring Drugs decreased by 10.12 million CNY, in comparison to that in 2015. The proportion of revenue from Key Monitoring Drugs decreased by 11.49% from 2015 to 2019. The per capita drug cost of Key Monitoring Drugs gradually decreased, this resulted in a saving of 580.07 CNY from 2015 to 2019. The DRPs of Key Monitoring Drugs decreased by 45.50% from 2015 to 2019. Through administrative intervention, prescription review, information management, and pharmaco-economicevaluation, a scientific management system of Key Monitoring Drugs has been established, which can standardize the use of Key Monitoring Drugs and reduce their cost. Conclusion Clinical pharmacists' interventions assisted in early detection Drug-related problems of Key Monitoring Drugs and prevention of the consequent patient harms.
doi:10.21203/rs.3.rs-56430/v1 fatcat:mekvvqwv3ncgvfi5c2moprqviu